Autoimmune hepatitis (AIH) is an autoimmune liver disease that is characterized by a progressive destruction of the liver parenchyma and the development of liver fibrosis. We aimed to examine the relationship between circulating cytokines/chemokines and the Mac-2 binding protein glycosylation isomer (M2BPGi) levels in Japanese patients with autoimmune hepatitis (AIH).
Introduction
Autoimmune hepatitis (AIH) is an immune-mediated liver disease characterized by elevated serum-IgG and circulating autoantibodies. [1] Corticosteroids alone or in combination with immunosuppressants are the mainstay therapies for patients with AIH. [2] In most cases, these therapies result in biochemical remission, a treatment end-point in AIH. [3] However, some AIH patients develop liver cirrhosis and liver failure at initial presentation. [4, 5] Hepatic inflammation is regulated by the activities of immune cells including lymphocytes, Kupffer cells, hepatocytes, and hepatic stellate cells. [6] Serum cytokines/ chemokines are thought to be linked to the pathogenesis of AIH by activating these hepatic immune cells. [7] Previous studies reported that levels of circulating inflammatory cytokines/ chemokines reflect liver damage in patients with AIH. [8] However, the relationship between cytokines/chemokines and hepatic inflammation in AIH patients remains unresolved.
Mac-2 binding protein glycosylation isomer (M2BPGi) is a serum biomarker for liver fibrosis caused by chronic viral hepatitis and nonalcoholic fatty liver disease. [9, 10] Although M2BPGi levels are correlated with liver fibrosis, serum M2BPGi values are increased in patients with acute liver injury suggesting M2BPGi may reflect liver inflammation. [11] More recently, Umemura et al reported that M2BPGi levels represented a simple and reliable surrogate marker of liver fibrosis in patients with primary biliary cholangitis (PBC). [12] Nishikawa et al also reported that M2BPGi was a useful marker for assessing liver histological findings in AIH patients. [13] However, there is no available data regarding the effects of immunosuppressive treatments on M2BPGi levels in patients with AIH.
In the present study, we analyzed the serum levels of cytokines/ chemokines and examined the relationship between these cytokines and clinical parameters to elucidate putative biomarkers for immune-mediated liver injury in patients with AIH. Another aim of the present study was to examine the relationship between M2BPGi levels and inflammatory cytokines and liver histological findings in patients with AIH.
Patients and methods

Study population
Patients with well-documented and untreated AIH were enrolled from the National Hospital Organization (NHO)-AIH-livernetwork database, a multicenter registry for Japanese patients with AIH. [5] The diagnosis of AIH was made according to the diagnostic criteria defined by International Autoimmune Hepatitis Group [14] , including a raised IgG level and presence of organspecific and non-organ-specific autoantibodies, presence of interface hepatitis and portal plasma cell infiltration on liver histology and the absence of other liver diseases of known etiology. Patients were excluded from the study if there was histological evidence of cholangitis or non-alcoholic steatohepatitis. Patients positive for hepatitis B virus surface antigen or HCV RNA were also excluded. Patients with other causes of liver disease, such as excess alcohol or drug use, were excluded based on reviews of their appropriate history and investigations. As controls, patients with chronic hepatitis C (untreated CHC, n = 32; female/male = 16/16; mean age, 56.2 ± 7.8 years; aspartate aminotransferase (AST), 43.4 ± 23.6 IU/L; alanine transaminase (ALT), 54.1 ± 39.0 IU/L), total bilirubin (TB), 0.8 ± 0.4 mg/d were included. As controls for autoimmune disease, SLE patients (n = 27; female/male = 22/5; untreated SLE = 12) satisfying American College of Rheumatology classification criteria were included. Mean age was 35.2 ± 13.4 years, mean age at diagnosis was 30.0 ± 12.5 years, mean disease duration 4.5 ± 5.6 years. Aspartate aminotransferase (AST), 38.1 ± 35.5 IU/L; alanine transaminase (ALT), 38.4 ± 72.9 IU/L); total bilirubin (TB), 0.8 ± 0.8 mg/d. Fifteen patients had been treated with steroid (mean prednisolone doses; 21.3 ± 21.9 mg/day), and 9 patients had been treated with steroid plus immunosuppressive agents. Nine patients were complicated with lupus nephritis and 6 patients were complicated with neuropsychiatric SLE (NPSLE). The study was approved by the Ethics Committee of the NHO Central Internal Review Board and participating NHO liver-network hospitals. Written informed consent was obtained from each individual.
Multiplex cytokine assay
We performed a multiplex cytokine bead assay blindly and in parallel using the Bio-plex Pro Human Cytokine assay (Bio-Rad, Hercules, CA) and Milliplex MAP Human Cytokine/Chemokine panel 1 (Millipore, Billerica, MA) according to the manufacturers' instructions as described previously. [15] The subjects' baseline demographic characteristics were compared using Fisher's exact test for discrete variables and the Wilcoxon test for continuous variables. The Kruskal-Wallis test followed by Dunn's multiple comparisons test was used to compare cytokine levels between groups. To rank the cytokine levels, we performed a multivariate classification algorithm termed random forest analysis (RFA), [16] using the R package RandomForest (http:// cran.r-project.org/web/packages/randomForest/) ver. 4.6-12 software, as previously described. [17] 2.3. Enzyme-linked immunosorbent assay for sICAM-1and IP-10 Serum concentrations of sICAM-1and IP-10 were measured using human sICAM-1 or IP-10 immunoassay kit (R&D Systems, Minneapolis, MN) according to the manufacturer's instruction.
Measurement of M2BPGi
Serum M2BPGi level was directly measured with the HISCL M2BPGi reagent kit (Sysmex, Kobe, Japan) using an automatic immunoanalyzer HISCL-5000 (Sysmex, Hyogo, Japan). M2BPGi levels were indexed using the following equation: The range of measurement is 0.1 to 20 COI [18] .
Staging of hepatic fibrosis
Liver biopsies were taken by fine-needle aspiration (16G or 18G sonopsy) guided by US. Liver tissue specimens were fixed in 10% formalin, embedded in paraffin, and stained with hematoxylin and eosin. They were evaluated for hepatic fibrosis stage by a pathologist according to the criteria of Desmet et al. [19] 2.6. Statistical analysis
The Chi-square test and Mann-Whitney U tests were applied to detect significant associations. Correlations between continuous variables were analyzed by the Pearson correlation test. Results for non-normally distributed continuous variables were summarized as mean or medians (interquartile ranges) and were compared by the Mann-Whitney U test. Paired data were analyzed by non-parametric tests using the Wilcoxon signed-rank test for the comparison of paired data.
Results
Baseline characteristics of patients
The demographic data of the enrolled AIH patients are shown in Table 1 . There were 14 males and 63 females with a median (range) age of 64 (21-83) years. Using the AIH scoring system, [14] 49 patients had more than 15 points (definite AIH) and the remaining 28 patients had 10 to 15 points (probable AIH). Regarding histological findings, in terms of the degree of inflammation activity, A3 was observed in 37 patients, A2 in 27 and A1 in 11. In terms of liver fibrosis stage, F4 was observed in 1 patient, F3 in 24, F2 in 14, F1 in 33, and F0 in 3. The M2BPGi values (pretreatment) in all AIH patients ranged between 0.33 and 16.9 (mean value 4.87). In 2 patients, liver biopsy was not performed due to medical reasons.
Identification of combinational biomarkers specific for AIH in attack by Random Forest Analysis and Logistic Regression Analysis
We selected 31 untreated AIH patients with paired serum samples before and after treatment and measured their serum levels of multiple cytokine/chemokines using the multiplex cytokine bead assay. The serum levels of 11 cytokines (IL-4, IL-8, IL-10, IL-18, TNF-a, sICAM-1, sVCAM-1, CCL-3, CCL-4 CCL-22, and CXCL10) were significantly elevated in the untreated AIH patients compared with those receiving 4 weeks of steroid therapy (Table 2 ). To determine the most important predictor to discriminate untreated active AIH from treated inactive AIH, we ranked the cytokines by importance using the random forest analysis (RFA). Hierarchical clustering with heatmaps based on the Spearman correlation coefficients between active AIH and inactive AIH (Fig. 1) . Although the exact identity of T cells that contribute to pathogenesis of AIH remains unknown, possible alterations in theTh1 (cellular immunity) and Th2 (humoral immunity) balance may play a role in liver cell injury. [20] It appears that an increased Th2 cytokines, such IL-10, IL-4 and proinflammatory cytokines/chemokines are increased in untreated AIH patients, [7] whereas we focused on the cytokines most Table 1 Baseline characteristics of 77 Japanese autoimmune hepatitis (AIH) Type 1 patients.
Characteristics n = 77
Female, n/total (%) 63 (81. Cytokine profile of autoimmune hepatitis (AIH) patients pre or post treatment pg/ml ( * ng/ml).
Cytokine AIH pre-treatment (n = 31) AIH posttreatment (n = 31) downregulated by steroid treatment, sICAM-1 and CXCL-10 (interferon-g-inducible protein 10;IP-10). We subsequently measured the serum concentrations of sICAM-1 and IP-10 in all AIH patients by specific ELISAs (Fig. 2) . Serum levels of sICAM-1 and IP-10 were elevated in AIH patients compared with chronic hepatitis C patients (sICAM-1; AIH: 1732.8 ± 1076.8 ng/ ml, CHC: 605.7 ± 85.7 ng/ml, IP-10; AIH: 914.5 ± 732.6 pg/ml, CHC: 487.9 ± 356.8 pg/ml) or SLE patients (sICAM-1; 461.4 ± 157.1 ng/ml, IP-10;735.6 ± 870.6 pg/ml).
Relationship between circulating sICAM-1 and IP-10 and liver function tests
To investigate the relationship between sICAM-1 or IP-10 and standard liver function parameters, we examined correlations between circulating sICAM-1 and serum levels of ALT or TB. A positive correlation was observed between serum levels of sICAM-1 and ALT or TB (Fig. 3) . Similarly, a positive correlation was observed between serum levels of IP-10 and ALT or TB (Fig. 4) .
Relationship between M2BPGi and liver fibrosis or necroinflammation
We demonstrated that serum levels of M2BPGi were elevated in AIH patients compared those with chronic hepatitis C as well as those with another autoimmune disease, SLE (Fig. 5) . To evaluate whether serum M2BPGi correlated with liver histology, we evaluated serum M2BPGi levels in AIH patients sub-grouped according to the staging of liver fibrosis (Fig. 6) . The mean M2BPGi values in each fibrosis stage (F0-F4) were 4.0 ± 3.0 COI in F0-F1, 4.7 ± 2.4 COI in F2, and 6.1 ± 4.3 COI in F3+F4. The values of M2BPGi were increased according to the stage of liver fibrosis (Fig. 6) . The M2BPGi values at each liver inflammation grading (A1-A3) were also evaluated by necroinflammatory grade (Fig. 6 ). The mean M2BPGi values for each necroinflammatory grade (A1-A3) were 3.3 ± 3.4 COI in A1, 4.6 ± 3.0 COI in A2, and 5.4 ± 3.8 COI in A3. The values of M2BPGi were increased according to the grade of liver inflammation (Fig. 6 ).
Whereas there was no significant correlation between serum levels of sICAM-1/IP-10 and liver fibrosis or inflammation scores (Fig. 7) . In addition, there was a correlation between sICAM-1 or IP-10 levels and those of M2BPGi in AIH patients (Fig. 8) . We stratified AIH patients by excluding patients with advance liver fibrosis stage (> F3) to minimize the effect of liver fibrosis against the values of circulating M2BPGi. We found a strong correlation between serum sICAM-1 or IP-10 levels and M2BPGi in AIH patients without advance liver fibrosis stage (Fig. 9) .
Changes in M2BPGi by corticosteroid therapy
Circulating levels of M2BPGi were measured before and after corticosteroid therapy in paired serum samples from 57 AIH patients. Serum levels of sICMA-1 and IP-10 were downregulated by corticosteroid therapy in AIH patients (Fig. 10A, B) . Similarly, M2BPGi was upregulated in untreated AIH patients and downregulated following glucocorticoid treatment of the same patients (Fig. 10C ). There was a significant difference in M2BPGi values before and after corticosteroid therapy in AIH patients.
Discussion
A comparative study of serum levels of various cytokines and chemokines in AIH patients before and after steroid therapy revealed the increased expression of a series of proinflammatory cytokines and chemokines. Among these cytokines/chemokines, we focused on combinational biomarkers for the acute phase of AIH consisting of IP-10 and sICAM-1. In our study, IP-10 levels were correlated with AIH disease severity, which is in line with previous studies of other liver diseases. Intracellular adhesion molecule-1 (ICAM-I), a member of the immunoglobulin (Ig) supergene family, [21] plays an important role in the recruitment of various inflammatory cells, antigen presentation and lymphocyte cytotoxicity. [22] Inflammatory cytokines, such as TNF-a and IL-1b enhance the expression of ICAM-I on hepatocytes.
[23] Levels of sICAM-1 are increased in inflammatory conditions of the liver indicating they might be related to the severity of liver disease or response to treatment. [24] Our demonstration of elevated sICAM-1 levels may be explained by the cytokine-induced upregulation of ICAM-1 expression by lymphocyte infiltration and inflamed or damaged hepatocytes. These findings suggest that elevated levels of circulating sICAM-1 could be linked with cytokine-mediated liver inflammatory process in AIH. Of note, serum sICAM-1 or IP-10 levels correlated with circulating l M2BPGi levels in the present study. Previous studies demonstrated that M2BPGi was a prognostic factor for liver fibrosis in various chronic liver diseases. [9] However, the interactions of serum M2BPGi and levels of serum cytokines in autoimmune liver diseases remain unclear. To the best of our knowledge, this is the 1st study to investigate the relationship between serum M2BPGi and proinflammatory cytokines in patients with liver diseases. Our data indicate that serum M2BPGi values are elevated in patients with AIH, and that they correlate with serum IP-10 and sICAM-1 levels, which are involved in promoting active AIH from inactive AIH.
Furthermore, elevated serum M2BPGi levels were rapidly reduced following immunosuppressive treatment in AIH patients. These findings suggest that M2BPGi may not be just a liver fibrosis marker but also a useful biomarker for immunemediated hepatic injury. Umemura et al reported that M2BPGi levels were significantly correlated with histological activity grade in PBC patients. [12] Mishikawa et al demonstrated that M2BPGi was a useful predictor for liver histological findings in patients with AIH. [13] Our results demonstrating that M2BPGi values correlated with liver inflammation in AIH are consistent with the finding of Nishikawa et al. [12] In our study, elevated levels of the liver-specific biomarker M2BPGi were not increased in patients with SLE, another autoimmune disorder. However, M2BPGi values correlated with the circulating levels of IP-10 and sICAM-1 in SLE patients. These results may increase our understanding of the role of M2BPGi in autoimmune disease and its implications in the cytokine network. M2BPGi is a useful biomarker for liver fibrosis in chronic liver disease. [25] It is unclear whether circulating M2BPGi values are influenced by immune-mediated hepatic inflammation in AIH. Our data confirmed that circulating M2BPGi values correlated with autoimmune-mediated liver damage in AIH and that its levels were rapidly reduced by steroid treatment. These findings suggest that M2BPGi is likely to reflect other factors not limited to liver fibrosis such as hepatic inflammation or injury. Hepatic stellate cells (HSCs) secrete M2BPGi, which may serve as a messenger between HSCs and Kupffer cells via Mac2, which is expressed in Kupffer cells. [26] Therefore, M2BPGi is a surrogate marker for assessing HSC activation. Our findings suggest that cytokines/chemokines are implicated in HSC activation, M2BPGi induction and the interaction between HSCs and Kupffer cells via M2BPGi. These findings also suggest that M2BPGi levels are influenced by hepatic inflammation and decreased following immunosuppressive treatment reflecting immune-mediated liver inflammation and damage in AIH.
There were limitations in our study. First, this was a retrospective study. Second, liver biopsy has a limitation of Figure 5 . Serum levels of M2BPGi in autoimmune hepatitis (AIH) patients (n = 77), patients with chronic hepatitis C (HCV, n = 32) and patients with systemic lupus erythematosus (SLE, n = 27). The vertical lines indicate the range and the horizontal boundaries of the boxes represent the 1st and 3rd quartiles. Results were compared by non-parametric Mann-Whitney U test. AIH = autoimmune hepatitis, M2BPGi = Mac-2 binding protein glycosylation isomer. sampling error for assessing the degree of fibrosis and liver inflammation. Third, our sample size was relatively small for analysis.
Conclusion
Serum levels of M2BPGi were increased in patients with untreated AIH and were decreased following steroid treatment resulting in a clinical improvement. This marker might reflect liver fibrosis as well as autoimmune-mediated hepatic inflammation in parallel to the induction of hepatitis-related inflammatory cytokines.
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